AmbioPharm is not named or identified on the U.S. Department of Defense’s Section 1260H list of “Chinese Military Companies.” AmbioPharm has not been designated a “Biotechnology Company of Concern” under the BIOSECURE Act.

Ambiopharm is a privately held U.S. headquartered peptide API contract development and manufacturing organization (CDMO), with FDA inspected facilities in North Augusta, South Carolina and Shanghai, China.